Ex­clu­sive: Ready to ex­it 'qui­et mode,' joint en­ti­ty Ven­tyx de­buts its im­mune mod­u­la­tor pipeline with $114M round

In the crazy world of biotech fi­nanc­ing, pre­co­cious star­tups are scor­ing big checks from in­vestors with some of­ten laugh­ably ear­ly da­ta. Now, a Cal­i­for­nia im­mune mod­u­la­tion play­er is ready to un­cloak with a nine-fig­ure down pay­ment in hand and an un­usu­al­ly ad­vanced pipeline.

Encini­tas-based Ven­tyx Bio­sciences has scored a $114 mil­lion eq­ui­ty in­vest­ment to try three dif­fer­ent im­mune mod­u­la­tor tar­gets in the clin­ic, one of which is al­ready squared up for a Phase II study in ul­cer­a­tive col­i­tis.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.